Chest
Original Research: Diffuse Lung DiseasePredicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary Function
Section snippets
Materials and Methods
We identified pulmonary function tests (PFTs) for patients with IPF through interstitial lung disease databases from the Royal Brompton and Harefield National Health Service Foundation Trust, National Jewish Health, and the University of Michigan Health System from 1981 through 2008. Patients were diagnosed with IPF either through surgical lung biopsy or characteristic chest CT scan.1, 24 For each patient, sex, age, and every PFT they had performed at their home center were captured for
Patient Population
A total of 4,431 PFTs were analyzed from 734 patients (characteristics are in Table 1). Fewer patients had baseline Dlco measurement performed than FVC: 657 vs 730, respectively. If a patient had subsequent Dlco measured, their data would return to the analysis for later years. An aggregate mean FVC and Dlco were recorded for each year of the analysis and were remarkably consistent between the years: within 5% predicted for FVC and 4% predicted for Dlco.
Due to losses to follow-up, we compared
Discussion
In a large, multicenter, retrospective cohort of patients with IPF, we report (1) the change in pulmonary function in the prior year does not predict the change in pulmonary function in the subsequent year, (2) declines in the pulmonary function in the prior year predicts mortality in the following year, and (3) commonly used study end points such as mortality and decline in pulmonary function occur with greatest frequency the first year after presentation.
Attempts to enrich study populations
Conclusions
In summary, short-term, clinically significant declines in FVC or Dlco correlate with an increased risk of mortality in the following 12 months. However, declines in these measures do not predict subsequent declines in pulmonary physiology. These data should help inform the next generation of treatment trials in IPF.
Acknowledgments
Author contributions: Dr Flaherty had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Dr Schmidt: contributed to study conception and design; data acquisition, analysis, and interpretation; and preparation and final approval of the manuscript and served as principal author.
Ms Tayob: contributed to data analysis and revision and final approval of the manuscript.
Dr Han: contributed to data analysis and
References (28)
- et al.
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial
Lancet
(2009) - et al.
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Lancet
(2011) - et al.
Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis
Chest
(2005) - et al.
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management
Am J Respir Crit Care Med
(2011) - et al.
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis
Am J Respir Crit Care Med
(2005) - et al.
High-dose acetylcysteine in idiopathic pulmonary fibrosis
N Engl J Med
(2005) - et al.
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis
Am J Respir Crit Care Med
(2008) - et al.
BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis
Am J Respir Crit Care Med
(2011) - et al.
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
N Engl J Med
(2004) - et al.
Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial
Am J Respir Crit Care Med
(2008)
Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study
Am J Respir Crit Care Med
Pirfenidone in idiopathic pulmonary fibrosis
Eur Respir J
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis
N Engl J Med
The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis
Am J Respir Crit Care Med
Cited by (0)
Part of this article was presented at the American Thoracic Society International Conference, May 13-18, 2011, Denver, CO, and in abstract form (Schmidt SL, Han MK, Tayob N, et al. Am J Respir Crit Care Med. 2011;183:A5299).
Funding/Support: This study was supported by National Institutes of Health [Grant HL093351 to Dr Han and Grants K24HL11316, R01HL19743 and HL007749 to Dr Flaherty].
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.